Fig. 11: CCDC7_241aa inhibits tumor growth in PDX models and synergizes with enzalutamide and docetaxel.

A Representative images of tumors from PDX-1 (CRPC-313) models treated with vehicle or CCDC7_241aa. B, C Tumor volume measurements over time and tumor weight in PDX-1 models treated with vehicle or CCDC7_241aa. Data are presented as mean ± SD. D Representative images of tumors from PDX-2 (CRPC-651) models treated with vehicle or CCDC7_241aa. E, F Tumor volume measurements over time and tumor weight in PDX-2 models treated with vehicle or CCDC7_241aa. G Dose-response curve illustrating the effect of CCDC7_241aa on cell viability in PC3 prostate cancer cells, with an IC50 value of 12.970 µM. H Dose-response curves showing the effect of docetaxel (DTX) on cell viability in PC3 cells pre-treated with control or CCDC7_241aa. I Combination index (CI) plot for PC3 cells treated with a combination of docetaxel (DTX) and CCDC7_241aa, indicating a synergistic effect (CI < 1). J Dose-response curve illustrating the effect of CCDC7_241aa on cell viability in LNCaP prostate cancer cells. K Dose-response curves showing the effect of docetaxel (DTX) on cell viability in LNCaP cells pre-treated with control or CCDC7_241aa. L Combination index (CI) plot for LNCaP cells treated with a combination of docetaxel (DTX) and CCDC7_241aa, indicating a synergistic effect (CI < 1). M Dose-response curve illustrating the effect of CCDC7_241aa on cell viability in VCap prostate cancer cells. N Dose-response curve illustrating the effect of CCDC7_241aa on cell viability in 22RV1 prostate cancer cells. Combination index (CI) plot for VCap (O) and 22RV1 (P) cells treated with a combination of enzalutamide (Enz) and CCDC7_241aa, indicating a synergistic effect (CI < 1). Statistical significance is indicated by asterisks: *p < 0.05, **p < 0.01, and ***p < 0.001.